Alphabet’s Verily, once a flagship "moonshot" venture exploring connected diabetes therapies and robot surgery, is closing its medical device division and laying off staff, according to a Business Insider memo. While the exact number of job cuts was not disclosed, the move follows Alphabet’s broader 2023 restructuring that eliminated 12,000 positions and redirected resources toward AI and data infrastructure. CEO Stephen Gillett highlighted past achievements such as the Dexcom G7 continuous glucose monitor and the Stargazer VNRC drug‑targeting system, which screened 7,800 patients. Verily will now concentrate on its core mission of precision health, data, and AI.
Leer más →